Autoři: Gaye Arslan 1 ; Gökçenur Karakelleoğlu 1; Cihan Karadağ 2 Působiště autorů: Department of Obstetrics and Gynecology, Okan University Hospital, Istanbul, Turkey 1; Department of Obstetrics and Gynecology, Medicana Hospital, Istanbul, Turkey 2 Vyšlo v časopise: Ceska Gynekol 2025; 90(6): 457-462 Kategorie: Původní práce doi: https://doi.org/10.48095/cccg2025457
Cíl: Zjistit, zda se index triglyceridů/glukózy (TyG-index – triglycerides), produkt akumulace lipidů (LAP – lipid accumulation product) a index viscerálního tuku (VAI – visceral adiposity index) liší u mladých pacientek se syndromem polycystických ovarií (PCOS – polycystic ovary syndrome) ve srovnání se skupinou bez PCOS, a zkoumat vztah mezi těmito markery a rizikem kardiovaskulárních onemocnění (CVO – cardiovascular disease) u pacientek s PCOS. Materiály a metody: Do studie bylo zahrnuto 192 žen s PCOS a 148 zdravých žen bez PCOS s daným věkem a indexem tělesné hmotnosti (BMI). Byly stanoveny sérové androgeny, pohlavní hormony, lipidy, glukóza nalačno, inzulin nalačno a hladiny N-terminálního mozkového natriuretického peptidu (Nt-probnp). Byl proveden perorální glukózový toleranční test se 75 g glukózy. Byl vypočítán index homeostatického modelu – inzulinová rezistence (HOMA-IR) a Matsudův index citlivosti na inzulin. Byly stanoveny hladiny TyG-index, LAP a VAI. Výsledky: TyG, LAP a VAI byly u pacientek s PCOS signifikantně vyšší než v kontrolní skupině (p = 0,001 vs. p = 0,001 vs. p = 0,001). HOMA-IR byl signifikantně vyšší u pacientek s PCOS a Matsuda ISI byl signifikantně nižší u pacientek s PCOS (p = 0,001 vs. p = 0,001). Hladiny Nt-probnp byly u pacientek s PCOS signifikantně vyšší (p = 0,001). Hladiny celkového testosteronu a androstendionu v séru signifikantně korelovaly s TyG, LAP a VAI. Nt-probnp signifikantně koreloval s TyG, LAP a VAI. LDL pozitivně a HDL negativně koreloval s TyG-indexem, LAP a VAI. Závěr: Pacientky s PCOS mají zvýšené hodnoty TyG-indexu, LAP a VAI. TyG index, LAP a VAI mohou naznačovat zvýšené riziko kardiovaskulárních onemocnění a hyperandrogenizmu u pacientek s PCOS.
kardiovaskulární onemocnění – syndróm polycystických ovárii – triglyceridový/glukózový index – produkt akumulace lipidů – index viscerální tukové tkáně
1. Azziz R, Carmina E, Chen Z et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016; 2 : 16057. doi: 10.1038/nrdp.2016.57.
2. Dunaif A, Book CB. Insulin resistance in the polycystic ovary syndrome. Clinical research in diabetes and obesity. Springer 1997 : 249–274.
3. Liou TH, Yang JH, Hsieh CH et al. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril 2009; 92 (6): 1960–1965. doi: 10.1016/j.fertnstert.2008.09.003.
4. Lord J, Thomas R, Fox B et al. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006; 113 (10): 1203–1209. doi: 10.1111/j.14 71-0528.2006.00973.x.
5. Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab 2010; 95 (9): 3347–3351. doi: 10.1210/jc.2010-0288.
6. Abbasi F, Reaven GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides× glucose versus triglyceride/high-density lipoprotein cholesterol. Metabolism 2011; 60 (12): 1673–1676. doi: 10.1016/j.metabol.2011.04.006.
7. Khan SH, Sobia F, Niazi NK et al. Metabolic clustering of risk factors: evaluation of Triglyceride-glucose index (TyG index) for evaluation of insulin resistance. Diabetol Metab Syndr 2018; 10 : 74. doi: 10.1186/s13098-018-0376-8.
8. Sánchez‐Íñigo L, Navarro‐González D, Fernández‐Montero A et al. The TyG index may predict the development of cardiovascular events. Eur J Clin Invest 2016; 46 (2): 189–197. doi: 10.1111/eci.12583.
9. Cristello F, Cela V, Artini PG et al. Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol 2005; 21 (6): 340–352. doi: 10.1080/09513590500463360.
10. Mirmiran P, Bahadoran Z, Azizi F. Lipid accumulation product is associated with insulin resistance, lipid peroxidation, and systemic inflammation in type 2 diabetic patients. Endocrinol Metab (Seoul) 2014; 29 (4): 443–449. doi: 10.3803/EnM.2014.29.4.443.
11. Brończyk-Puzoń A, Jagielski P, Kulik-Kupka K et al. Usefulness of a new anthropometric indicator-VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome. Adv Clin Exp Med 2017; 26 (5): 825–828. doi: 10.17219/acem/61100.
12. Amato MC, Giordano C, Galia M et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33 (4): 920–922. doi: 10.2337/dc09-1825.
13. Zheng SH, Li XL. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Gynecol Endocrinol 2016; 32 (3): 177–183. doi: 10.3109/09513590.2015.1111327.
14. ESHRE TR, Group A-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81 (1): 19–25. doi: 10.1016/j.fertnstert.2003.10.004.
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22 (9): 1462–1470. doi: 10.2337/diacare.22.9.1462.
16. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 2008; 6 (4): 299–304. doi: 10.1089/met.2008.0034.
17. Onat A, Avci GŞ, Barlan M et al. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004; 28 (8): 1018–1025. doi: 10.1038/sj.ijo.0802695.
18. Olsen MH, Wachtell K, Tuxen C et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004; 22 (8): 1597–1604. doi: 10.1097/01.hjh.0000125451.28861.2a.
19. Wild RA, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95 (5): 2038–2049. doi: 10.1210/jc.2009-2724.
20. Fauser BC, Tarlatzis BC, Rebar RW et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97 (1): 28.e25–38.e25. doi: 10.1016/j.fertnstert.2011.09.024.
21. Lambrinoudaki I, Kazani MV, Armeni E et al. The TyG index as a marker of subclinical atherosclerosis and arterial stiffness in lean and overweight postmenopausal women. Heart Lung Circ 2018; 27 (6): 716–724. doi: 10.101/ j.hlc.2017.05.142.
22. Jones H, Sprung VS, Pugh CJ et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 2012; 97 (10): 3709–3716. doi: 10.1210/jc.2012-1382.
23. Macut D, Antić IB, Bjekić-Macut J et al. Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. Hormones (Athens) 2016; 15 (1): 35–44. doi: 10.14310/horm.2002.1592.
24. Wiltgen D, Benedetto I, Mastella L et al. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod 2009; 24 (7): 1726–1731. doi: 10.1093/humrep/dep072.
25. Abruzzese GA, Cerrrone GE, Gamez JM et al. Lipid accumulation product (LAP) and visceral adiposity index (VAI) as markers of insulin resistance and metabolic associated disturbances in young argentine women with polycystic ovary syndrome. Horm Metab Res 2017; 49 (1): 23–29. doi: 10.1055/s-0042-113463.
26. Cascella T, Palomba S, De Sio I et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 2008; 23 (1): 153–159. doi: 10.1093/humrep/ dem356.
27. Androulakis II, Kandaraki E, Christakou C et al. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2014; 81 (3): 426–431. doi: 10.1111/cen.12447.
28. Franzosi MG. Should we continue to use BMI as a cardiovascular risk factor? Lancet 2006; 368 (9536): 624–625. doi: 10.1016/S0140-67 36 (06) 69222-2.
29. Amato MC, Verghi M, Galluzzo A et al. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 2011; 26 (6): 1486–1494. doi: 10.1093/humrep/ der088.
30. Oh JY, Sung YA, Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity (Silver Spring) 2013; 21 (8): 1690–1694. doi: 10.1002/oby.20096.
ORCID of author
G. Arslan 0000-0002-3332-3178
Submitted/Doručeno: 7. 8. 2025
Accepted/Přijato: 16. 9. 2025
Gaye Arslan, MD
Department of Obstetrics and Gynecology
Okan Universitesi Hastanesi
İçmeler, Aydınlı Yolu Caddesi. No: 2
34947 Tuzla, Istanbul
Turkey
gaye.arslan@okan.edu.tr
Zvyšte si kvalifikaci online z pohodlí domova
Nemáte účet? Registrujte se
Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.
